Guangzhou Baiyunshan Pharmaceutical Holdings (0874) has a market capitalization of approximately HK
Guangzhou Baiyunshan Pharmaceutical Holdings's trailing twelve-month P/E ratio is 12.1x, with a price-to-book (P/B) of 0.9x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
Guangzhou Baiyunshan Pharmaceutical Holdings runs a net profit margin of 3.8%, a gross margin of 16.0%, and an operating margin of 4.1%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
Guangzhou Baiyunshan Pharmaceutical Holdings reported revenue of ¥77.7B for fiscal year 2025, with net income of ¥3.0B and earnings per share (EPS) of 1.83. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Guangzhou Baiyunshan Pharmaceutical Holdings offers a trailing dividend yield of about 3.9%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.
Guangzhou Baiyunshan Pharmaceutical Holdings carries a debt-to-equity ratio of 0.59x and a current ratio of 1.60x, with a market beta of 0.25. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Guangzhou Baiyunshan Pharmaceutical Holdings (0874) the key facts are: market cap HK
Get Guangzhou Baiyunshan Pharmaceutical Holdings's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.